Ganaxolone, for Adult Focal Onset Seizures, Fails to Meet Primary Endpoint in Phase 3 Study, Marinus Announces
News
Marinus Pharmaceuticals recently reported that their drug candidate ganaxolone, developed for adults with drug-resistant focal onset epilepsy, did not meet the primary endpoint in a Phase 3 clinical trial. The trial demonstrated no ... Read more